Article Text

PDF
A polymorphism in the gene encoding the Fcγ IIIA receptor is a possible genetic marker to predict the primary response to infliximab in Japanese patients with rheumatoid arthritis
  1. S Tsukahara,
  2. K Ikari,
  3. E Sato,
  4. H Yamanaka,
  5. M Hara,
  6. T Tomatsu,
  7. S Momohara,
  8. N Kamatani
  1. Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
  1. Katsunori Ikari, MD, PhD, Institute of Rheumatology, Tokyo Women’s Medical University, 10–22 Kawada, Shinjuku, Tokyo 162-0054, Japan; kikari{at}ior.twmu.ac.jp

Statistics from Altmetric.com

The prediction of treatment outcome of patients with rheumatoid arthritis (RA) may avoid wasting time and cost of treatment, and allow better targeting of aggressive treatment. Recently, an amino acid-changing polymorphism in the gene encoding the Fcγ IIIA receptor (FcγRIIIA), valine (V)/phenylalanine (F) (rs396991), was found to be associated with increased likelihood of response to tumour necrosis factor (TNF)-α inhibitors in the treatment of RA.1 The aim of the present study was to determine whether this FcγRIIIA V/F polymorphism is associated with treatment outcome of infliximab (the first TNF-α inhibitor approved in Japan) in Japanese patients with RA.

The study was approved by the Tokyo Women’s Medical University Genome Ethics Committee. The …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.